Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers
Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers
复制标题
贝沙罗汀在癌症预防、治疗和抗耐药性中的新作用
DOI：
10.1080/14737140.2018.1449648
复制
发表时间：
2018-03
影响因子：
3.3
通讯作者：
Xia Liqun
中科院分区：
文献类型：
--
作者：
Shen Danyang;Yu Xiaoming;Wu Yan;Chen Yuanlei;Li Gonghui;Cheng Feng;Xia Liqun
摘要引言：视黄酸X受体通过转录调控在肿瘤细胞增殖、分化、凋亡和血管生成中发挥重要作用。贝沙罗汀是一种特异性RXR激动剂，已被FDA批准用于皮肤T细胞淋巴瘤（CTCL）的临床治疗。在过去的十年中，它在各种肿瘤中的癌症预防和治疗潜力一直在研究中。涵盖的领域：本文就贝沙罗汀治疗多种肿瘤的临床试验和基础研究进行综述。专家评论：总体而言，贝沙罗汀是一种积极合理的化学预防和治疗各种癌症的药物，其与其他细胞毒性药物或靶向药物的联合方案可显著增强疗效，同时由于其不重叠的副作用而降低毒性。然而，在大多数情况下，只有一个贝沙罗汀治疗患者亚群从贝沙罗汀给药中获益。RXR的水平可以作为癌症如非小细胞肺癌、急性髓性白血病、乳腺癌、甲状腺癌和黑色素瘤中贝沙罗汀反应的初步指标。进一步鉴定和验证贝沙罗汀反应生物标志物可能最终导致贝沙罗汀在CTCL以外的癌症上的个性化临床应用。
ABSTRACT Introduction: Retinoic acid X receptors play key roles in tumor cell proliferation, differentiation, apoptosis and angiogenesis via transcriptional regulation. Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL). Its cancer prevention and treatment potentials in various tumors have been under investigation over the past decade. Areas covered: This review summarizes the efficacy and underlying mechanisms of bexarotene for the treatment of multiple cancers based on the launched clinical trials as well as the basic studies. Expert commentary: In general, bexarotene is an active and reasonable chemoprevention and treatment for various cancers and its combination regimen with other cytotoxic agents or targeted drugs may significantly enhance efficacy and at the same time reduce toxicity due to their nonoverlapping side effects. However, only a subpopulation of bexarotene treated patients benefited from bexarotene administration in most cases. The level of RXRs may serve as a preliminary indicator for the bexarotene response in cancers such as non-small cell lung cancer, acute myeloid leukemia, breast cancer, thyroid cancer and melanoma. Further identification and verification of bexarotene response biomarkers may finally lead to the personalized clinical application of bexarotene on cancers beyond CTCL.
登录
查看更多内容
影响因子：
37.3
作者：
Klopper JP;Sharma V;Berenz A;Hays WR;Loi M;Pugazhenthi U;Said S;Haugen BR
通讯作者：
Haugen BR
影响因子：
--
作者：
Budgin, JB;Richardson, SK;Rook, AH
通讯作者：
Rook, AH
影响因子：
8.8
作者：
Illidge, T.;Chan, C.;Counsell, N.;Morris, S.;Scarisbrick, J.;Gilson, D.;Popova, B.;Patrick, P.;Smith, P.;Whittaker, S.;Cowan, R.
通讯作者：
Cowan, R.
影响因子：
13.8
作者：
Jacob A Sepmeyer;J. Greer;T. Koyama;J. Zic
通讯作者：
Jacob A Sepmeyer;J. Greer;T. Koyama;J. Zic
影响因子：
3.4
作者：
Seo HS;Woo JK;Shin YC;Ko SG
通讯作者：
Ko SG